Review article · 2026 · Open access
In vivo immune cell engineering from bench to clinical reality
Pharmaceutical Science Advances, 4, 100131 · Published 8 July 2026 · DOI 10.1016/j.pscia.2026.100131
In brief
“In vivo immune cell engineering from bench to clinical reality” is a 2026 review article by Hui Yu and 6 co-authors, published in Pharmaceutical Science Advances. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Pharmaceutical Science Advances.
- Citations
- 0
- References
- 167
- Authors
- 7
Abstract
Adoptive immune cell therapies, exemplified by chimeric antigen receptor T cells, have transformed the treatment of hematological malignancies. However, their broader clinical application is limited by complex ex vivo manufacturing, high cost, and safety concerns. In vivo immune cell engineering has emerged as an alternative strategy that delivers genetic instructions directly to immune cells, thereby generating or modulating therapeutic immune cells within the body and reducing the reliance on individualized in vitro operations. These advances underscore the need for a systematic evaluation of this emerging field. Therefore, this review systematically summarizes the mechanistic principles and delivery strategies underlying in vivo immune cell engineering, with an emphasis on in vivo CAR-T cell generation and the engineering of other immune cells. We then discuss major viral and non-viral delivery platforms and clarify how these platforms influence cargo delivery, cell specificity, and functional immune-cell programming. We further discuss recent preclinical and emerging clinical advances across cancer, autoimmune diseases, and degenerative diseases, while examining key translational challenges, including delivery specificity, off-target effects, controllability, persistence, and manufacturing standardization. Overall, although the field of in vivo immune cell engineering is advancing rapidly, its clinical success will depend on coordinated improvements in delivery precision, therapeutic efficacy, safety, and controllable immune-cell programming.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Yu, H., Han, M., Zhao, X., Tang, C., Jia, Y., Jing, W., & Jiang, X. (2026). In vivo immune cell engineering from bench to clinical reality. Pharmaceutical Science Advances, 4, 100131. https://doi.org/10.1016/j.pscia.2026.100131
MLA 9
Yu, Hui, et al. “In vivo immune cell engineering from bench to clinical reality.” Pharmaceutical Science Advances, vol. 4, 2026, p. 100131. https://doi.org/10.1016/j.pscia.2026.100131.
Chicago
Yu, Hui, Maosen Han, Xiaotian Zhao, Chunwei Tang, Yanda Jia, Weiqiang Jing, and Xinyi Jiang. 2026. “In vivo immune cell engineering from bench to clinical reality.” Pharmaceutical Science Advances 4: 100131. https://doi.org/10.1016/j.pscia.2026.100131.
Harvard
Yu, H. et al. (2026) ‘In vivo immune cell engineering from bench to clinical reality’, Pharmaceutical Science Advances, 4, p. 100131. doi:10.1016/j.pscia.2026.100131.
IEEE
H. Yu et al., “In vivo immune cell engineering from bench to clinical reality,” Pharmaceutical Science Advances, vol. 4, p. 100131, 2026, doi: 10.1016/j.pscia.2026.100131.
BibTeX
@article{yu2026vivo,
title = {{In vivo immune cell engineering from bench to clinical reality}},
author = {Yu, Hui and Han, Maosen and Zhao, Xiaotian and Tang, Chunwei and Jia, Yanda and Jing, Weiqiang and Jiang, Xinyi},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100131},
doi = {10.1016/j.pscia.2026.100131},
url = {https://doi.org/10.1016/j.pscia.2026.100131}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- chimeric antigen receptor
- viral vectors
- off-target effects
- CAR T cell persistence
- production standardization
- hematologic malignancies
- autoimmune disease
- degenerative diseases
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Yu, H., Han, M., Zhao, X., Tang, C., Jia, Y., Jing, W., & Jiang, X. (2026). In vivo immune cell engineering from bench to clinical reality. Pharmaceutical Science Advances, 4, 100131. https://doi.org/10.1016/j.pscia.2026.100131
How many times has this paper been cited?
0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Pharmaceutical Science Advances: sign in and open the PDF from this page.
Who wrote this paper?
Hui Yu, Maosen Han, Xiaotian Zhao, Chunwei Tang, Yanda Jia, Weiqiang Jing, Xinyi Jiang.
What is the DOI of this paper?
10.1016/j.pscia.2026.100131, permanently at https://doi.org/10.1016/j.pscia.2026.100131. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.